PT - JOURNAL ARTICLE AU - Shibao, Cyndya AU - Peche, Vivek S. AU - Williams, Ian M. AU - Samovski, Dmitri AU - Pietka, Terri A. AU - Abumrad, Naji N. AU - Gamazon, Eric AU - Goldberg, Ira J. AU - Wasserman, David AU - Abumrad, Nada A. TI - Microvascular insulin resistance associates with enhanced muscle glucose disposal in CD36 deficiency AID - 10.1101/2024.02.16.24302950 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.16.24302950 4099 - http://medrxiv.org/content/early/2024/02/18/2024.02.16.24302950.short 4100 - http://medrxiv.org/content/early/2024/02/18/2024.02.16.24302950.full AB - Dysfunction of endothelial insulin delivery to muscle associates with insulin resistance. CD36, a fatty acid transporter and modulator of insulin signaling is abundant in endothelial cells, especially in capillaries. Humans with inherited 50% reduction in CD36 expression have endothelial dysfunction but whether it is associated with insulin resistance is unclear. Using hyperinsulinemic/euglycemic clamps in Cd36-/- and wildtype mice, and in 50% CD36 deficient humans and matched controls we found that Cd36-/- mice have enhanced systemic glucose disposal despite unaltered transendothelial insulin transfer and reductions in microvascular perfusion and blood vessel compliance. Partially CD36 deficient humans also have better glucose disposal than controls with no capillary recruitment by insulin. CD36 knockdown in primary human-derived microvascular cells impairs insulin action on AKT, endothelial nitric oxide synthase, and nitric oxide release. Thus, insulin resistance of microvascular function in CD36 deficiency paradoxically associates with increased glucose utilization, likely through a remodeling of muscle gene expression.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03012386Funding StatementThis study was funded by: National Institute of Health RO1DK111175 (NAA, CAS, NNA), NHLBI R01HL157584 (CAS), NHLBI R01 HL045095 (IJG, NAA) and Clinical Translational Science Award (CTSA) 5UL1TR002243-03 (CAS), Washington University Nutrition and Obesity Center (NORC, NIH P30 DK056341).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies were approved by the Vanderbilt Institutional Review Board and conducted in accordance with institutional guidelines. All subjects provided informed consent. The study was included in clinicaltrials.gov, identifier: NCT03012386I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors